Jun 21, 2022, 10:09 AM by

Optibrium™, a developer of software for drug discovery, today announced it has secured further investment from existing investors Kester Capital, a leading UK mid-market private equity firm. Funding will further drive company expansion and commercial growth of its AI-enabled drug discovery technology.

Jun 21, 2022, 10:09 AM by

The biologics consulting services market is driven by increasing R&D in advanced therapies like cell & gene therapies, growing biologics regulatory approvals and significant VC fundings for biologics segment.

Jun 21, 2022, 10:09 AM by

Jun 21, 2022, 10:09 AM by

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Jun 21, 2022, 01:00 AM by User Not Found

Bio-IT World | A first in the world of organs-on-a-chip, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have come up with a lymphoid follicle (LF) model that can be used to probe the function of the immune system and predict its response to vaccines—including the three (Pfizer, Moderna, and J&J) currently in use for the prevention of COVID-19. “We hit upon the recipe that works and, in retrospect, it makes sense given what happens naturally,” says senior staff scientist Girija Goyal, Ph.D.

Jun 20, 2022, 10:30 AM by

The team of Biopharma PEG Scientific Inc. owns the most qualified and talented synthetic and medicinal chemists. We can provide a wide range of high purity monodispersed PEG products of multi functionalized groups in milligram to hundreds of kilograms or greater with GMP standard manufacturing capability.

Jun 20, 2022, 10:30 AM by

Pemetrexed is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC). It is also being studied in the treatment of other types of cancer.

Jun 20, 2022, 10:30 AM by

BioAgilytix Labs, LLC (“BioAgilytix”), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, today announces the appointment, effective immediately, of Euan Menzies as Chairman and CEO. Jim Datin is retiring from his executive management role but will continue to serve as a non-executive member of the Board of Directors.

Jun 17, 2022, 09:10 AM by

Jun 17, 2022, 09:08 AM by

YewMaker and Connect in Pharma announce today that the winners of the new Sustainable Medicines Packaging Awards will be announced at an in-person champagne ceremony at the Connect In Pharma event in Geneva on 14 September 2022. The new awards, run by sustainable healthcare pioneers YewMaker, will showcase and celebrate sustainable innovations revolutionising pharmaceutical packaging, with Gold, Silver and Bronze award winners under two categories.

Jun 17, 2022, 01:00 AM by User Not Found

Bio-IT World | Recent advances in the commercialization of neuroscience data acquisition technology have enabled a quickly growing collection of massive brain activity and behavioral datasets. Within the data lie exciting promises of solving how the brain generates behavior, and how it might be better healed when diseased or disturbed. But interpreting these large, high-dimensional datasets isn’t easy. We need modern, collaborative solutions that help scale data management, analysis, and knowledge sharing.

Jun 16, 2022, 09:39 AM by

Earlier this month, the management of Alfa Chemistry announced the launch of varieties of chemical fluorophores for researchers worldwide. Those newly released fluorophores, including BODIPY fluorophores, cyanine fluorophores, rhodamine fluorophores, and fluorescein fluorophores, can be widely used for bioanalysis, environmental monitoring, clinical diagnosis, fluorescence staining, as well as other application scenarios.

Jun 16, 2022, 01:00 AM by User Not Found

Bio-IT World | “Thirty to 40% of clinical trial costs are associated with actually just the manual retyping of [EHR] data [into the clinical trial system], and it leads to reporting delays and a number of other inefficiencies,” Adam Asare, chief data officer at the Quantum Leap Healthcare Collaborative/UCSF, told the Bio-IT World Conference & Expo audience last month. Asare shared a solution to that problem: a collaboration with OpenClinica that won the team a Bio-IT World Innovative Practices Award.

Jun 15, 2022, 09:29 AM by

Creative Biogene recently developed the C. elegans lysis/DNA extraction kits (CDC-k108) are now available to worldwide clients and partners.

Jun 15, 2022, 09:29 AM by

Creative Biogene announced the release of Bacillus subtilis cultivation service using flexible fermentation and cultivation strategies to help customers in obtaining high-yield and bioactive B. subtilis bioproducts.

Jun 15, 2022, 09:29 AM by

MOBILion Systems Inc. delivers technical presentations and unveils new applications areas for its HRIM instrument, MOBIE, at ASMS 2022.

Jun 15, 2022, 09:29 AM by

mdgroup appoints LaQuinta Jernigan as Chief Operating Officer Executive leadership appointment to drive seamless client experiences in patient- servicing and digitally enabled clinical trials

Jun 15, 2022, 01:00 AM by User Not Found

Bio-IT World | While the field of targeted protein degradation (TPD) continues its rapid expansion, with multiple TPD drugs now in clinical trials, researchers in Australia are jumping in at an earlier stage with “tag technology” to ensure the disease protein is worth designing a drug against in the first place. Their work—an extension of other tag-targeting protein degradation technologies—gives researchers the wherewithal to ask if, “the juice is worth the squeeze,” according to Rebecca Feltham, Ph.D., laboratory head in the Ubiquitin Signalling Division of the Walter and Eliza Hall Institute.

Jun 14, 2022, 09:29 AM by

Jun 14, 2022, 01:00 AM by User Not Found

Bio-IT World | A significantly heightened risk of breast cancer has two well-known culprits—mutations to the tumor suppressor genes BRCA1 and BRCA2—but more than 40% of the time they are black-box “variants of uncertain significance.” Using a new data-sharing innovation known as federated analysis, however, an international team of researchers has categorized 16 of these uncertain variants as benign or likely benign so their carriers may be able to have their clinical risk of disease managed properly and avoid the risk of invasive and irrevocable surgeries.